Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine.
Azithromycin, rifabutin, and rifapentine were used to treat or prevent disseminated Mycobacterium avium complex (MAC) infections produced in rats immunosuppressed with cyclosporine. Animals with bacteremic infections were treated 1 week after intravenous inoculation with 10(7) CFU of MAC with azithromycin, 100 mg/kg of body weight administered subcutaneously for 5 days and then 75 mg/kg on Monday, Wednesday, and Friday, or with rifabutin or rifapentine, 20 mg/kg administered intraperitoneally on Monday through Friday. All three drugs showed efficacy after 1 and 2 months. Rifabutin cleared the organisms from tissues more rapidly than azithromycin or rifapentine. To approximate prophylaxis, treatment was started 2 weeks before intravenous inoculation with 10(4) organisms. MAC infections were undetectable in treated animals after 4 months, while control animals had disseminated infections. These findings support the rationale for clinical trials of treatment and prophylaxis with these agents. The cyclosporine-treated rat appears to be a useful model in which to evaluate compounds for the treatment and prophylaxis of disseminated MAC infections.
Infectious Disease Service, Memorial Sloan-Kettering Cancer Center, New York 10021.
S T
ST
Brown
F F
FF
Edwards
E M
EM
Bernard
W
W
Tong
D
D
Armstrong
D000818:Animals; D000995:Antitubercular Agents / Q000032:analysis / Q000627:therapeutic use*; D017963:Azithromycin; D016572:Cyclosporine / Q000097:blood / Q000494:pharmacology*; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000032:analysis / Q000627:therapeutic use; D008297:Male; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017828:Rifabutin; D012293:Rifampin / Q000031:analogs & derivatives* / Q000032:analysis / Q000627:therapeutic use; D012294:Rifamycins / Q000032:analysis / Q000627:therapeutic use*; D014018:Tissue Distribution
D000995:Antitubercular Agents; D012294:Rifamycins; D017828:Rifabutin; D004917:Erythromycin; D017963:Azithromycin; D016572:Cyclosporine; D012293:Rifampin; C018421:rifapentine